JIUYUAN GENE2566.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, JIUYUAN GENE (2566.HK) trades at a P/E of 7.98x, P/B of 0.66x, P/S of 0.86x, and a dividend yield of 1.26%.
Longitudinal percentile comparison: P/E sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 27th percentile within its industry and the 36th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 6.39%, ranking at the 100th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 0.0 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Breaking down the total shareholder yield: 1.26% comes from cash dividends, with an implied ~5.13% from buybacks — a fairly balanced mix of both channels. JIUYUAN GENE operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2566 · SEHK: 2566 · 2566
Want the full picture on whether JIUYUAN GENE (2566.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 7.98 | ||||||
| P/B (MRQ) | 0.66 | ||||||
| P/S (TTM) | 0.86 | ||||||
| Dividend Yield | 1.26% | ||||||
| Buyback + Div Yield | 6.39% |